Inspire Medical Systems (NYSE:INSP) Price Target Raised to $60.00 at JPMorgan Chase & Co.

Inspire Medical Systems (NYSE:INSP) had its price objective boosted by research analysts at JPMorgan Chase & Co. from $54.00 to $60.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price target would indicate a potential downside of 4.77% from the company’s current price.

Several other equities analysts also recently issued reports on INSP. Weiss Ratings downgraded shares of Inspire Medical Systems from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, May 6th. Piper Sandler boosted their price objective on shares of Inspire Medical Systems from $55.00 to $60.00 and gave the stock a “neutral” rating in a research note on Tuesday. Oppenheimer upgraded Inspire Medical Systems from a “market perform” rating to an “outperform” rating and set a $85.00 price target on the stock in a research report on Tuesday. Evercore set a $54.00 price objective on Inspire Medical Systems in a research report on Tuesday. Finally, Freedom Capital raised Inspire Medical Systems to a “strong-buy” rating in a research note on Tuesday, June 30th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have assigned a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, Inspire Medical Systems has an average rating of “Hold” and a consensus price target of $72.56.

Inspire Medical Systems Price Performance

Shares of NYSE INSP traded up $10.78 during mid-day trading on Tuesday, hitting $63.00. 1,428,104 shares of the stock traded hands, compared to its average volume of 1,165,299. The company has a market cap of $1.82 billion, a PE ratio of 14.08, a price-to-earnings-growth ratio of 5.08 and a beta of 0.70. Inspire Medical Systems has a twelve month low of $38.91 and a twelve month high of $147.03. The firm has a 50 day simple moving average of $46.15 and a two-hundred day simple moving average of $55.17.

Inspire Medical Systems (NYSE:INSP) last issued its earnings results on Monday, August 3rd. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.38. The business had revenue of $200.58 million during the quarter, compared to analysts’ expectations of $194.72 million. Inspire Medical Systems had a return on equity of 10.35% and a net margin of 14.33%.The business’s revenue for the quarter was down 7.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.45 EPS. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. On average, equities research analysts anticipate that Inspire Medical Systems will post 0.93 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Inspire Medical Systems

Hedge funds have recently added to or reduced their stakes in the business. CWM LLC boosted its holdings in shares of Inspire Medical Systems by 216.1% during the 4th quarter. CWM LLC now owns 354 shares of the company’s stock worth $33,000 after buying an additional 242 shares in the last quarter. Havemeyer Place LP bought a new stake in shares of Inspire Medical Systems in the 4th quarter valued at $39,000. V Square Quantitative Management LLC bought a new stake in shares of Inspire Medical Systems in the 4th quarter valued at $40,000. Smartleaf Asset Management LLC lifted its position in shares of Inspire Medical Systems by 84.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock valued at $42,000 after acquiring an additional 205 shares during the period. Finally, Daiwa Securities Group Inc. boosted its stake in Inspire Medical Systems by 38.7% during the second quarter. Daiwa Securities Group Inc. now owns 466 shares of the company’s stock worth $60,000 after acquiring an additional 130 shares in the last quarter. 94.91% of the stock is currently owned by institutional investors.

More Inspire Medical Systems News

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Q2 earnings and revenue exceeded expectations. Inspire reported adjusted earnings of $0.14 per share, versus analyst expectations for a $0.24 loss, while revenue of $200.6 million topped the $194.7 million consensus estimate. Inspire Medical Systems Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Management raised fiscal 2026 guidance. The company now expects earnings per share of $1.05 to $1.45, above the $0.91 consensus estimate, and revenue of $835 million to $875 million, broadly centered around Wall Street’s $848.9 million forecast. Inspire Announces Q2 Results and Raised Guidance
• Positive Sentiment: Oppenheimer upgraded INSP. The firm raised its rating from “market perform” to “outperform” and assigned an $85 price target, implying substantial upside from the recent trading level. Benzinga analyst rating report
• Neutral Sentiment: Analyst views remain mixed. Robert W. Baird increased its price target from $54 to $59 but maintained a “neutral” rating, indicating that the firm still sees limited near-term upside after the recent rally. The Fly analyst rating report
• Negative Sentiment: Underlying comparisons were weaker. Quarterly revenue declined 7.6% from the prior year, and earnings fell from $0.45 per share to $0.14, highlighting continued year-over-year pressure despite the quarterly beat. Inspire Medical Systems earnings report

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.